Large Differences between Focal and Diffuse Patterns of Stable CAD

PCI is far more successful at reducing ischemia when treating focal stable coronary artery disease (CAD). However, there were no differences in symptoms between both types of CAD. 

Grandes diferencias entre angioplastia en enfermedad focal vs difusa

Physiological assessment with pressure wire pullback can be used to distinguish focal vs diffuse CAD, even though the relevance of this distinction has not been looked at closely. 

Using the ORBITA database, researchers tested PCI efficacy against placebo in both types of CAD patterns (focal vs diffuse). They observed the impact of these patterns on stress echocardiography ischemia and symptom end points. 

164 patients were assessed with iFR pullback before randomization. Focal CAD was defined as iFR drop >0.03 within 15 mm. Greater distances were defined as diffuse CAD. 

Of the 85 patients in the ORBITA PCI branch, 48 showed focal lesions and 37 diffuse CAD. IN the placebo arm (n=79) 35 had focal lesions and 44 diffuse CAD.

Focal stenosis was associated with significantly lower FFR and iFR vs. diffuse pattern patients (mean FFR and iFR, focal 0.60±0.15 and 0.65±0.24, diffuse 0.78±0.10 and 0.88±0.08, respectively, p<0.0001).


Read also: New Markers of Aortic Stenosis Define Asymptomatic Patients.


Stress echocardiography ischemia saw significantly greater reduction with PCI when patients showed a focal pattern, vs. a diffuse pattern (p<0.05). 

PCI did not show significant variation in exercise time pre and post randomization. This continued to be true after stratifying patients according to CAD pattern. 

PCI was superior to placebo when using the Seattle Angina Questionnaire both in frequency and freedom from symptoms. However, these differences continued to be true and similar when stratifying patients into focal and diffuse CAD. 

Conclusion

PCI achieve greater ischemia reduction with focal CAD vs. diffuse. There were no differences in symptom end points. 

CIRCINTERVENTIONS-120-009891

Original Title: Placebo-Controlled Efficacy of Percutaneous Coronary Intervention for Focal and Diffuse Patterns of Stable Coronary Artery Disease.

Reference: Christopher A Rajkumar et al. Circ Cardiovasc Interv. 2021 Aug 3;CIRCINTERVENTIONS120009891. Online ahead of print. doi: 10.1161/CIRCINTERVENTIONS.120.009891.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis

In cases of intermediate coronary lesions, functional assessment is recommended to aid the decision-making process regarding revascularization. There are several tools currently used to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...